Pharmaceutical Technology

DECEMBER 25, 2023

Magrolimab is under clinical development by Gilead Sciences and currently in Phase II for Ureter Cancer.

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

Magrolimab is under clinical development by Gilead Sciences and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer.

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

Magrolimab is under clinical development by Gilead Sciences and currently in Phase I for Fallopian Tube Cancer.

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

Magrolimab is under clinical development by Gilead Sciences and currently in Phase II for Small-Cell Lung Cancer.

40

40

PhRMA

MARCH 23, 2023

Last month marked the one-year anniversary of the reignited Cancer Moonshot, the White House’s ambitious goal of reducing the death rate from cancer by at least 50% over the next 25 years. But more needs to be done.

291

291

pharmaphorum

JULY 7, 2021

The UK’s long-awaited Life Sciences Vision strategy has been published, setting out the government’s stall as it tries to deliver on its promise to keep the country at the forefront of the sector. billion ($2.2 billion) in financing between March and end-May, ranking third after the US hubs in Massachusetts and San Francisco.

Documentation 59

Documentation Vaccines 59

Fierce Pharma

FEBRUARY 5, 2024

By Matthew Cotter, PhD, Vice President, Global Medical Affairs, Prostate Cancer, Pfizer Oncology Sponsored by Pfizer Inc. Ongoing scientific research is needed to better understand prostate cancer and identify treatment options to help address unmet needs of patients.

52

52

PharmaVoice

APRIL 10, 2024

TAE Life Sciences is bringing radiation-based cancer therapy to clinical trials globally in the coming years.

119

119

pharmaphorum

FEBRUARY 16, 2024

Gilead Sciences has paused enrolment in clinical trials of its CD47 drug magrolimab in solid tumours, a week after dropping it for blood cancers.

124

124

STAT

APRIL 15, 2024

Nelsen, managing director of ARCH Venture, had made a name and fortune off crazy ideas, but generally it was the science that sounded crazy: engineering cells to cure cancer, finding drugs to slow aging. “This is a crazy idea,” Sato said. This new idea was financially crazy.

141

141

STAT

APRIL 18, 2024

An ongoing investigation into data integrity at Dana-Farber Cancer Institute has resulted in a string of retractions, the latest of which is a 2006 Science paper co-authored by institute president and CEO Laurie Glimcher.

144

144

STAT

MARCH 14, 2024

We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver disease. Read the rest…

113

113

STAT

MARCH 18, 2024

Want to stay on top of the science and politics driving biotech today?  Today we ponder the vast open spaces of Boston’s unused life sciences labs, see a new biopharma IPO in the works, and expect a label expansion for some CAR-T blood cancer therapies. Read the rest…

Labelling 99

Labelling FDA 99

Fierce Pharma

NOVEMBER 30, 2023

The sizzling antibody-drug conjugate (ADC) field is at the center of another major life sciences deal. | The sizzling antibody-drug conjugate field is at the center of another major life sciences deal. billion in cash to acquire ImmunoGen, maker of the ovarian cancer treatment Elahere.

127

127

STAT

JANUARY 22, 2024

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed. Continue to STAT+ to read the full story…

Chemotherapy 136

Chemotherapy 136

pharmaphorum

FEBRUARY 8, 2024

Gilead Sciences has said it will no longer develop its CD47-targeting antibody magrolimab in blood cancers after data suggested that patients taking the drug in clinical trials were more likely to die than those in control groups.

119

119

STAT

APRIL 10, 2024

Want to stay on top of the science and politics driving biotech today?  Today, we get some optimism from the new director of the National Cancer Institute, despite a brain drain playing out in the industry and stagnant funding numbers.   Sign up  to get our biotech newsletter in your inbox. Read the rest…

Insurance 84

Insurance 84

STAT

MARCH 4, 2024

A participant in a 2020 report from the National LGBT Cancer Network said: “There are no guidelines for cancers that are more prevalent among Trans women. ” That same year, the National Academies of Sciences, Engineering, and Medicine issued a hallmark report  on the health and well-being of LGBTQ+ people.

Insurance 122

Insurance 122

STAT

APRIL 8, 2024

Want to stay on top of the science and politics driving biotech today?  We have news for you from the annual meeting of the American Association for Cancer Research, and also from the annual meeting of the American College of Cardiology.   Sign up  to get our biotech newsletter in your inbox. Hi, it’s Meghana.

101

101

STAT

NOVEMBER 30, 2023

We discuss why AbbVie is spending $10 billion on a cancer-focused company that spent four decades on the path to its first FDA approval, a deal with implications for biotech in 2023 and for a burgeoning area in oncology.

FDA 98

FDA 98

Pharma Mirror

APRIL 17, 2024

As an authority in radiation oncology, Dr. Khuntia joining the board of directors validates BNCT and the work TAE Life Sciences is doing to make it a mainstay of modern cancer care IRVINE, Calif.- FASTRO, to its esteemed Board of Directors.

52

52

STAT

JUNE 21, 2023

A genomic test for the human papillomavirus has shown promise in early-stage trials, raising hopes that it could bolster cervical cancer screening among women living in sub-Saharan Africa, the region with the highest rates of cervical cancer deaths worldwide. Read the rest…

Documentation 98

Documentation 98

pharmaphorum

JUNE 7, 2022

million people are diagnosed with a form of cancer, resulting in 1.9 million deaths, making cancer the second largest cause of mortality. Although Europe comprises only one eighth of the global population, cancer cases in the region make up a quarter of the world’s total. Exact Sciences’ work across the cancer continuum.

Chemotherapy 90

Chemotherapy Medical Schools 90

STAT

FEBRUARY 12, 2024

And while the occasion is most closely associated with ads for beer, cars, and soft drinks, pharma giant Pfizer dished out millions of dollars for its own message: “Here’s to science.” Read the rest…

Hospitals 141

Hospitals 141

STAT

MAY 7, 2024

At a panel at the Milken Institute 2024 Global Conference Monday, Bastani and other health care leaders addressed the rapidly growing applications of AI in science and health care. ” said MD Anderson Cancer Center Chief Data Officer Caroline Chung. ” to “What can I do with AI?”

128

128

STAT

OCTOBER 13, 2023

Want to stay on top of the science and politics driving biotech today?  Today, we learn about energy-sucking cancer cells, explore a map of the human brain, and update you on the downfall of Cassava Sciences.   Sign up  to get our biotech newsletter in your inbox. Have a good weekend. Read the rest…

98

98

STAT

FEBRUARY 12, 2024

There was a time when an allegation of data mishandling, scientific misconduct, or just a technical error felt like a crisis to Barrett Rollins, an oncologist and research integrity officer at Dana-Farber Cancer Institute. Nearly 80% of these comments were on health or life sciences studies. Now, it’s a Tuesday.

144

144

Outsourcing Pharma

OCTOBER 28, 2021

An expert from the decentralized study solutions company shares perspectives on the importance of inclusivity and solutions that could improve representation.

59

59

STAT

SEPTEMBER 6, 2023

Looking at the dizzying progress in cancer medicine over the last couple of decades, it’s easy to imagine that advances in synthetic biology or immunology will soon help cure or prevent more cancers. “We’re talking about early detection of cancers, multicancer early detection sort of approaches are happening.

126

126

STAT

DECEMBER 21, 2023

Understand how science, health policy, and medicine shape the world everyday. Don’t miss Nicholas Florko’s jaw-dropping investigation into medical marijuana businesses marketing their products for cancer or depression with no regulatory oversight. Sign up for our Morning Rounds newsletter  here. Good morning.

FDA 101

FDA 101

STAT

DECEMBER 6, 2023

Ovarian cancer owes its often-dismal prognosis to the late stage at which it’s typically discovered. If a tumor is found when it’s small and cancer cells haven’t spread, treatment works well for 90% of patients. “And after reading this paper, I think it remains an interesting idea.

124

124

STAT

APRIL 29, 2024

Want to stay on top of the science and politics driving biotech today?  Today, we learn there are some serious safety concerns around an experimental blood cancer drug from MorphoSys that has been the centerpiece of Novartis’ plan to acquire the company for $3 billion. Continue to STAT+ to read the full story…

Immunization 88

Immunization FDA Vaccines 88

STAT

OCTOBER 9, 2023

Delfi Diagnostics, a well-funded startup in the burgeoning field of creating blood tests to detect cancer, said on Monday that it is launching a new test, FirstLook Lung, to try to identify people who could most benefit from lung cancer screening.

Insurance 129

Insurance 129

STAT

NOVEMBER 7, 2023

Longtime cancer doctor Monica Bertagnolli is finally heading to the National Institutes of Health director’s office after a nearly two-year effort to install a permanent leader atop the $48 billion science agency.

144

144

STAT

OCTOBER 26, 2023

How do cancer drugs work? Our colleague Andrew Joseph joins us to explain the decades-old cancer-treating technology that had its star turn at this week’s big oncology conference in Europe. What makes biotech stocks go up? And why are venture capitalists so optimistic? Read the rest…

106

106

STAT

NOVEMBER 28, 2023

A study questioned colonoscopies as the gold standard of colon cancer screens. Exact Sciences, the maker of Cologuard, touts the accuracy of its colorectal cancer screening tests — but experts want more data. Then it raised a furor. Colonoscopies are time-consuming and unpleasant. How about a yogurt drink instead ?

77

77

STAT

JANUARY 17, 2024

Want to stay on top of the science and politics driving biotech today?  Damian here with the latest biotech startup to downsize, a novel idea in cancer treatment, and a few major catalysts on the calendar.   Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Read the rest…

88

88